Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (2186)	12/1/2000 7:47:17 AM
From: rkrw	Read Replies (1) \| Respond to of 52153

<<Mgt should better designed first two trials and protocols three years ago. No credit where isn’t deserved, my motto is. This trial is effort of new mgt.>> MZ, you're making my point. If mgt had done a better job the first time around, one would never have had the opportunity to buy this stock at low prices. The stock was at $4-$5 for months on end this year as the trial progressed. Point is an investor shouldn't give up on a biotech just because the first trial failed. If mgt is capable and the drug is sound, one can profit.